Kymera Therapeutics (KYMR) Misses Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update
August 9, 2022 7:00 AM EDTInitiated dosing in patient cohort (Part C) of IRAK4 degrader KT-474 Phase 1 trial, on track for data by year end
Phase 1 patient studies initiated for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs,initial data to be shared by year end
June 30, 2022 cash balance of $482.5 million, providing cash runway into 2025
Company to hold quarterly results call at 8:30 a.m. EST (877-317-6789 or +1 412-317-6789)
WATERTOWN, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a... More
